An interventional study of Integrating the HEAR score and hs POC troponin into pre hospital triage decision-making: in Non ST Segment Elevation Acute Coronary Syndrome, sponsored by Cyril Camaro. Recruiting at 3 sites in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.
Sponsored by Cyril Camaro · Not applicable, Interventional, and Other
RESEARCH QUESTION: Is a treatment strategy that includes direct referral to a PCI center for intermediate to high-risk patients with non-ST elevation acute coronary syndrome (NSTE-ACS), both cost-effective and non-inferior for major adverse cardiac events (MACE)? HYPOTHESIS: Prehospital triage with the modified [History-ECG-Age-Risk factors] (HEAR) score and a high sensitivity (hs) point-of-care troponin (POCT) leads to a faster diagnosis of ACS, faster time to coronary angiography (CAG) and/or treatment with PCI, shorter length of stay, quicker availability of ambulances and more satisfaction and quality of life of patients. STUDY DESIGN: Randomized clinical trial. STUDY POPULATION: Patients ≥18 years with an intermediate to high risk for NSTE -ACS (defined as a modified HEAR score ≥ 4) INTERVENTION: applying modified HEAR score and hs POCT to identify patients for direct rule out (very low risk), transfer to the nearest hospital for rapid rule-out and/or fast-track diagnosis by CT coronary imaging (intermediate risk) or direct referral to a PCI center for CAG (high risk).
USUAL CARE/COMPARISON: Assessment of ACS at the nearest hospital. In case PCI is scheduled: transfer to nearest PCI center.
OUTCOME MEASURES: primary endpoints: healthcare costs and non-inferiority for MACE (all cause death, confirmed ACS, re ACS, and unplanned PCI or CABG) at 30 days. Secondary: MACE after rule out ACS at 30 days, Quality of life (EQ5D5L) and cost-effectiveness at 12 months.
SAMPLE SIZE: 1048 patients. COST-EFFECTIVENESS ANALYSIS / BIA: It is expected that the intervention group will reduce healthcare costs and potentially improve health-related quality of life in this target population. Cost-effectiveness will be expressed as cost per QALY gained. We assume a large potential saving more than € 37 million if 100% implemented. TIME SCHEDULE: 48 months; 36 month inclusion, follow-up 12 months
Rationale: Each year, 335.000 patients in the Netherlands seek medical attention for acute chest pain. The majority of these patients (67%) are at intermediate to high risk of developing non-ST elevation acute coronary syndrome (NSTE-ACS). Immediate ambulance transport to the nearest emergency department (ED) remains the standard of care. The availability of clinical decision rules, along with new high-sensitivity (hs) POC troponin analyzers, presents new opportunities for the early identification of higher-risk patients, potentially improving healthcare logistic. Currently, only observational data are available regarding these groups. Randomized clinical trials (RCT) on a prehospital strategy that includes a rapid rule out or fast-track diagnosis care path for the intermediate risk group or direct referral to a PCI center for the higher risk group has not been studied in a RCT before. More data are needed on prehospital strategies in high-risk groups, focusing on costs and major adverse cardiac events (MACE).
Objective: To assess healthcare costs and safety (MACE) at 30 days of an integrated pre-hospital triage strategy using the [History-ECG-Age-Risk factors] HEAR score and hs POC troponin for patients at intermediate to high risk of NSTE ACS. Secondary objective includes MACE after rule-out ACS at 30 days and cost-effectiveness and quality of life at 12 months.
Study design: Randomized clinical trial (pragmatic strategy trial) Sample size calculation: 1048 patients. A MACE rate of 20% for all risk groups in both the standard and intervention groups: sample sizes of 476 per group to achieve 80% power to detect a non-inferiority margin of 0.0800. The reference group proportion is 0.2000, and the treatment group proportion is 0.2800 under the null hypothesis of inferiority. Power was calculated assuming the actual treatment group proportion is 0.2 Study population: Patients ≥18 years with an intermediate to high risk for NSTE-ACS (defined as a modified HEAR score ≥ 4) Intervention: applying modified HEAR score and hs POC troponin to identify patients for direct rule out (low risk), transfer to the nearest hospital for rapid rule-out and/or fast-track diagnosis in which non-invasive imaging is strongly recommended (intermediate risk) or direct referral to a PCI center (high risk).
Main study parameters/endpoints: primary endpoints: healthcare costs and non-inferiority for MACE (all cause death, confirmed ACS, re ACS, and unplanned PCI or CABG) at 30 days. Secondary: MACE after ruling out ACS at 30 days, Quality of life (EQ5D5L) and cost-effectiveness at 12 months.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Two-thirds of ACS patients are intermediate to high risk and standard hospital evaluation remain the standard of care. In this study the randomized group will receive a patient tailored prehospital management (conservative, local hospital with non-invasive imaging testing, or direct PCI referral). This strategy may safely reduce unnecessary hospitalizations, costs and efficient hospital transfers. While increasing the time to diagnosis of NSTE ACS
This is the only study on the registry with Cyril Camaro as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Integrating the HEAR score and hs POC troponin into pre hospital triage decision-making:
Other: Integrating the HEAR score and hs POC troponin into pre hospital triage decision-making:
intermediate and high risk patients referred to the nearest hospital for standard care. The ACS rule-out protocol follows the 2023 Guidelines of the European Society of Cardiology (ESC). In confirmed cases of ACS, patients should be scheduled for invasive coronary angiography within the recommended time window as outlined by the ESC guidelines
Integrating the HEAR score and hs POC troponin into pre hospital triage decision-making: low risk (HEAR score 4 and hs POC troponin \< 99th percentile upper reference limit (URL)) will be treated conservatively (i.e. referred to the general practitioner); intermediate risk (HEAR score 4 and onset symptoms \< 1 hour ago, HEAR score ≥5 and hs POC troponin \< 99th percentile URL or HEAR score 4-6 with intermediate elevated hs POC troponin (i.e. hs POC troponin between 1 and 3 times the 99th percentile URL) are admitted to the nearest hospital with a rapid rule out strategy or recommendation for fast-track coronary CT imaging (CTCA); high risk group (HEAR ≥ 7 ánd hs POC troponin \> 99th percentile URL or any HEAR score with hs POC troponin 3x \> 99th URL will be directly referred to a PCI center
Non-inferiority for MACE
MACE (% all cause death, confirmed ACS, re ACS, and unplanned PCI or CABG). Risk differences will be calculated along with 95% confidence intervals
Time frame: from enrollment to end of treatment at 30 days and 12 months
Healthcare costs
healthcare costs in EURO
Time frame: from enrollment to end of treatment at 30 days and 12 months
MACE after ruling out ACS
30-day incidence of MACE in %. Risk differences will be calculated along with 95% confidence intervals
Time frame: from enrollment to end of treatment at 30 days
Quality of life measured with the EQ5D5L
Quality of life
Time frame: from enrollment to end of treatment at 30 days and 12 months
Cost-effectiveness analysis (CEA)
Incremental cost-effectiveness ratios (ICERs) will be calculated
Time frame: from enrollment to end of treatment at 12 months
Plan to share: Undecided — It is anticipated that individual participant data (IPD) will be made available. A detailed and comprehensive data sharing strategy will be established in 2026
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.